Search Results 41-50 of 10916 for Antecedent

1. Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy - Mayo Clinic

   AML patients with a history of antecedent treatment for myelodysplasia (MDS), e.g. azacitidine or decitabine, remain eligible for treatment on this study.

2. A Study to Assess AC220 Given in Combination with Induction and Consolidation Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) - Mayo Clinic

   Diagnosis of AML following an antecedent hematologic disorder (diagnosis of myelodysplasia or myeloproliferative neoplasm by bone marrow aspirate and/or ...

3. Does the Critical Shoulder Angle Influence the Rotator Cuff Failure After Anatomic Shoulder Arthroplasty? - Mayo Clinic

   patients with glenoid dysplasia, rheumatoid arthritis, antecedent of prior surgery on the ipsilateral shoulder. Participating Mayo Clinic locations. Study ...

4. Therapeutic Plasma Exchange With Enfortumab Vedotin And Pembrolizumab For Treatment Of Bladder Cancers - Mayo Clinic

   ... antecedent to enrollment) * Measurable disease per RECIST version (v)1.1 * Eastern Cooperative Oncology Group (ECOG) performance status grade 0, 1, or 2

5. Temsirolimus and Bevacizumab in Treating Patients with Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer - Mayo Clinic

   AFP > three times normal and doubling in value in the antecedent 3 months. Child-Pugh A (≤ 6 points) or better liver status; Prior regional treatments for ...

6. Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older - Mayo Clinic

   Antecedent hematologic disease; Known adverse cytogenetic risk; Eastern Cooperative Oncology Group (ECOG) PS = 2. Patient must not have received definitive ...

7. Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia - Mayo Clinic

   ... antecedent blood count abnormalities, or myelodysplastic syndrome (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history ...

8. JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.

9. Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) - Mayo Clinic

   One prior cycle of therapy with an approved hypomethylating agent (HMA) such as azacitidine or decitabine is allowed for either an antecedent hematologic ...

10. Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome - Mayo Clinic

    Secondary MDS (defined as MDS developing in a subject with an antecedent hematologic disorder or any subject with prior chemotherapy or radiation exposure); ...